相关实验视频

Updated: Jun 19, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

探索阿克西提尼布在肺癌类瘤中多方面的抗瘤活性

Monica Oldani¹, Maria Celeste Cantone¹, Germano Gaudenzi¹

¹Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Milan, Italy.

Frontiers in endocrinology

|July 25, 2024

概括

阿克西替尼 (AXI) 通过间接破坏瘤DNA,导致细胞循环停止,显示出治疗肺癌 (LCs) 的潜力. 它的有效性依赖于DNA损伤和随后的衰老诱导在这些神经内分泌瘤.

科学领域:

在瘤学瘤学.
癌症研究癌症研究
药理学药理学是指药理学的学科.

背景情况:

肺癌 (LCs) 是神经内分泌瘤 (NETs),占所有NETs的20-25%和肺癌的1-2%.
NETs具有高度血管化,并过度表达血管生长因子受体 (VEGFR),使血管生成抑制成为治疗策略.
阿克西蒂尼布 (AXI) 是一种向VEGFR的药物,研究其治疗LC的潜力.

研究的目的:

评估在肺癌 (LC) 细胞系中阿克西替尼 (AXI) 的长期抗瘤活性.
研究AXI抗瘤作用背后的机制,包括细胞周期变化和细胞亡.
探索DNA损伤和衰老在AXI治疗作用中的作用.

主要方法:

三个LC细胞系 (NCI-H727,UMC-11,NCI-H835) 用它们各自的EC50AXI度进行了6天的治疗.
使用FACS分析和西白斑来评估细胞周期进展和细胞亡.
显微镜被用来观察衰老和线粒体灾难等机制.

主要成果:

AXI主要通过间接DNA损伤来阻止LC细胞系的瘤生长.
药物诱导各种反应,包括衰老和线粒体灾难,这取决于细胞系.
当DNA损伤受到缓解时,AXI的有效性会降低,如在NCI-H835细胞中所见.

结论:

通过影响LC细胞中的细胞活力和增殖,AXI显示出作为治疗剂的潜力.
DNA损伤和随后的衰老激活是AXI抗瘤功能的关键先决条件.
对AXI机制的进一步研究可以优化其用于治疗肺癌的使用.

关键词:

艾克西尼尼比 (Axitinib) 是一种细胞循环中的细胞循环.这是一种肺癌性肺癌.线粒体灾难的灾难有活性氧物种的反应性氧物种.衰老是一种老化.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...